Back to News
Market Impact: 0.38
Amneal Gains FDA Approval For Generic Lanreotide Injection; Launches Drug Immediately
Source: Nasdaq
Healthcare & BiotechProduct LaunchesRegulation & Legislation
Amneal Pharmaceuticals received FDA approval for its Lanreotide injection, a generic version of SOMATULINE Depot. The approval expands Amneal's generic-drug portfolio and creates a potential new revenue opportunity in the specialty injectable market.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.62
Ticker Sentiment
AMRX0.78
More News
- Google's Gemini becomes latest AI model to break out and hack computer systems
- After threatening to seize Greenland by force, Trump agrees to leave it with Denmark and boost military presence. ‘We will be very protective of it!’
- Japan has record 100,000 people aged over 100: How societies are ageing
- Google’s Gemini AI hacks 3 companies in security test, then stops
- Analysis-Russia sanctions bill gives Trump sweeping new tariff powers
- Anthropic selects Accenture as first embedded evaluator to help implement Amodei's slowdown proposal
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Tools for Private Equity Due Diligence: A Buyer Workflow
- Weekly Update: In-App Tutorials, Futures Data, and Watchlist Enhancements